A phase I clinical pharmacology study of SJP-0139 with a single-dose and multiple-dose administration in healthy male volunteers
Latest Information Update: 04 Jan 2019
At a glance
- Drugs SJP-0139 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Senju Pharmaceutical
- 28 Dec 2018 Status changed from active, no longer recruiting to completed.
- 28 Jun 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 19 Jan 2018 New trial record